Letter of Calaf sent to EU The Presidents of 32 pharmaceutical companies And they are calling for measures to prevent investors from leaving the US to the US in a mood of trade war.
In a letter addressed on April 11th to EU President Ursula von der Layen, the 32 Pharmaceuticals, Great and Medium -sized, promise to “increase” the share of the European market, which today represents 22.7% in world sales.
Without them, “in three months from today, scheduled investments of 16.5 billion euros could be transferred outside Europe,” warned NOVO NORDISK, PFIZER, ELI LILLY, ROCHE, SANOFI, MERCK, GSK and SERVIER in the letter in this letter that was released by many media and which came to the knowledge today.
Companies are calling for a competitive European market “that attracts, properly evaluates and rewards innovation”, estimating that “continuing commercial tensions will further accelerate the reduction in investment in research and growth and production in the European Union”.
As they say, this must be done by revising the pricing policy of drugs in Europe, which is less favorable than that applied to the United States, and a revision of the regulatory framework.
“The procedure for clinical trials carried out in several countries” must “shorten the procedure for the European Agency’s resources to increase innovative therapies, according to the signatories.
They also ask Brussels to “suspend and review” the directive aimed at improving the treatment of wastewater before being dismissed in the environment, “in order to prevent disproportionate burdens” for the sector.
Pharmaceuticals are currently exempt from the customs duties imposed by Washington. However, several pharmaceutical groups have recently announced investments to boost production in the United States: Eli Lilly $ 27 billion, $ 55 billion in the next 4 years by Johnson & Johnson.
Merck inaugurated vaccines in North Carolina, a $ 1 billion project.
The Swiss pharmaceutical giant Novartis announced on Thursday that it will invest $ 23 billion in the United States for five years to produce the basic drugs intended for American patients.